Outcomes and Safety of PD-1 Blockades Plus Anlotinib Regimen in Previously-Treated Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective, Exploratory Study.

Drug Des Devel Ther · 2026 · PMC13008505 · PMID 41884476

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Median PFS for patients with ICIs-pretreated was 5.8 months (95% CI: 3.99–7.62) versus 4.5 months (95% CI: 2.91–6.09) for ICI-naïve patients, and the patients with ICIs-pretreatment showed a trend toward better PFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.